Pfizer announced on Thursday that it is progressing in the development of a once-daily weight loss pill, which it anticipates will be competitive within the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) declined to approve Novo Nordisk’s once-weekly insulin. Additionally, a report from the U.S. Federal Trade Commission (FTC) revealed that pharmacy benefit managers (PBMs) are increasing drug prices.
Stay updated with these and other key pharmaceutical news highlights from this week.